Transparency Document
NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate V.2.2025
| Request Number | Guideline Page | Specific change request | Panel Decision | Comment | Institution Vote |
|---|---|---|---|---|---|
| 3843 |
CRIT-6
Prostate Submission from Invitae Corporation on 03-26-2024 |
For bullet point: “Personal history of prostate cancer with specific features:” Proposed change: Remove “with specific features” from bullet point and all subsequent bullet points in the “Personal history” section. |
Change not made |
Yes: 0 No: 33 Abstain:0 Absent:0 |
|
| 3844 |
TITLE
Prostate Submission from Invitae Corporation on 03-26-2024 |
Specific changes proposed: Guideline Title: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Proposed change: Add Prostate to the Title: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate |
Change made |
Yes: 34 No: 0 Abstain:0 Absent:0 |
|
| 2741 |
CRIT-6
Testing Criteria Submission from Myriad Genetics, Ambry Genetics, Illumina Inc., Quest Diagnostics on 03-07-2024 |
We request that the following criteria be added to the Testing Criteria for Prostate Cancer to make them consistent with the prior testing criteria in the NCCN Prostate Cancer guideline v4.2023 (page PROS-C 2 of 3):
On page CRIT-6, under the second arrow (“By family history and ancestry”) please add:
|
Change not made |
Yes: 0 No: 34 Abstain:0 Absent:0 |